跳至主要内容
临床试验/NCT01919710
NCT01919710已完成1 期

Phase 1 Study of rHSA/GCSF in Neutropenia After Chemotherapy of Cancer Patients

Tianjin SinoBiotech Ltd.1 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
29
试验地点
1
主要终点
Number of adverse events

研究概览

简要总结

Safety and efficacy studies of rHSA/GCSF fusion protein for injection in treatment of neutropenia induced by chemotherapy of cancer patients.

详细描述

A dosage climbing for the safety and efficacy studies for the neutropenia induced by chemotherapy cancer patients Repeat-dose studies for the safety and efficacy studied for the neutropenia.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • chemotherapy induced neutropenia

排除标准

  • treated with other biological drugs or other neutropenia therapy drugs

研究组 & 干预措施

rHSA/GCSF for injection

Experimental

rHSA/GCSF Start from 300mcg

干预措施: rHSA/GCSF (Drug)

结局指标

主要结局

Number of adverse events

时间窗: 14 days

Number of participants with adverse events as a measure for safety and tolerability after single and multiple dose of rHSA/GCSF

次要结局

  • AUC(14 days)

研究者

发起方
Tianjin SinoBiotech Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验